The guidelines also highlighted the higher incidence of GVHD in patients who received MOG before allogeneic transplantation in ATLL (81% versus 41%), thus recommending careful optimization of transplant preparation in SS patients and delaying it after MOG treatment. This evidence concerns the gene MOG and graft versus host disease.